Charter Oak Capital Management LLC acquired a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,003 shares of the company's stock, valued at approximately $337,000. Charter Oak Capital Management LLC owned 0.06% of SI-BONE as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Silvercrest Asset Management Group LLC grew its position in SI-BONE by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after purchasing an additional 350,970 shares during the period. American Century Companies Inc. lifted its position in shares of SI-BONE by 11.0% during the fourth quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Marshall Wace LLP grew its position in SI-BONE by 332.5% in the 4th quarter. Marshall Wace LLP now owns 264,523 shares of the company's stock worth $3,709,000 after purchasing an additional 203,361 shares in the last quarter. Nuveen Asset Management LLC increased its stake in SI-BONE by 17.8% in the 4th quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after buying an additional 190,830 shares during the last quarter. Finally, First Eagle Investment Management LLC purchased a new position in shares of SI-BONE in the 4th quarter worth approximately $2,600,000. Institutional investors and hedge funds own 98.11% of the company's stock.
SI-BONE Stock Down 1.5%
NASDAQ:SIBN traded down $0.28 during mid-day trading on Wednesday, reaching $18.82. The company's stock had a trading volume of 208,862 shares, compared to its average volume of 382,982. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $20.05. The stock has a fifty day moving average of $16.30 and a 200-day moving average of $15.63. The firm has a market capitalization of $801.97 million, a PE ratio of -20.46 and a beta of 0.94. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.
SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. Equities research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Wall Street Analysts Forecast Growth
SIBN has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th. Needham & Company LLC restated a "buy" rating and set a $24.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial upped their price objective on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th.
Read Our Latest Stock Analysis on SI-BONE
Insider Buying and Selling
In other SI-BONE news, insider Anthony J. Recupero sold 3,311 shares of the business's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total transaction of $46,850.65. Following the completion of the sale, the insider now directly owns 284,555 shares in the company, valued at $4,026,453.25. The trade was a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 9,585 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $19.76, for a total value of $189,399.60. Following the sale, the chief financial officer now owns 224,507 shares of the company's stock, valued at $4,436,258.32. This represents a 4.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 95,942 shares of company stock valued at $1,734,203. Corporate insiders own 4.00% of the company's stock.
SI-BONE Company Profile
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Further Reading

Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.